BioVie Highlights Potential Long COVID Treatment in Latest Broadcast

New York, Saturday, 19 September 2026.
BioVie presented Phase 2 trial results for its Long COVID drug bezisterim. While primary endpoints lacked overall statistical significance, high-symptom subgroup improvements offer potential for future trials.